Although many more women have health insurance now than before the enactment of the Affordable Care Act, gaps in women’s health coverage persist, leaving them vulnerable to higher costs and denied claims.
Although many more women have health insurance now than before the enactment of the Affordable Care Act (ACA), gaps in women’s health coverage persist, leaving them vulnerable to higher costs and denied claims, and threatening their economic security and physical health, according to a new report from The Commonwealth Fund.
The August 2016 report, by Dania Palanker, JD, MPP, of the National Women’s Law Center, and Karen Davenport, MPA, a researcher with The Commonwealth Fund, recommended that allowed variations within states’ “essential health benefits” benchmark plans be prohibited and that transparency and simplified language in plan documents be required.
The researchers examined qualified health plans from 109 insurers across 16 states for 2014, 2015, or both years to uncover the types and incidence of insurer exclusions that may disproportionately affect women’s coverage. They found that although insurers can no longer deny coverage or charge higher premiums based on gender because of the ACA, and all individual market plans must cover maternity services, birth control, mammograms, and mental health services, there are nonetheless 6 types of services frequently excluded from insurance coverage: treatment of conditions resulting from noncovered services, maintenance therapy, genetic testing, fetal reduction surgery, treatment of self-inflicted conditions, and preventive services. All of these aspects of health coverage are not covered by the ACA.
“Such exclusions can undermine a primary goal of the ACA: to improve women’s health and eliminate gender discrimination in health insurance markets,” the authors wrote.
The service exclusions identified are often described in health plan materials for consumers in language that is difficult to understand for people with limited health literacy, and often appear only in detailed plan documents that many consumers do not read. Thus, women purchasing insurance may be unaware of the exclusions and the effect they have on their coverage.
For example, in the category of conditions resulting from noncovered services, the authors explain that insurers may deny a claim for needed medical care after the provision of an excluded service, such as the treatment of an infection arising from a prophylactic mastectomy. In the study, 46 of the 109 insurers examined excluded coverage of services that are related to, or arise from, other noncovered services.
Another example cited is that 29 of the 109 insurers exclude coverage of maintenance therapy—treatments that maintain health but are not expected to lead to improvements—or exclude other ongoing medical treatments that “prevent regression of functions in conditions that are resolved or stable.” Nine of the 29 insurers omit both types of treatment. Women are more likely than men to have lupus, depression, chronic pain, and other chronic health conditions that require maintenance therapy, the study notes, and are also more likely to have breast and lung cancers, the 2 most common forms of cancer in women—conditions that also require maintenance therapy to prevent or slow their progression.
Another important gap is in preventive services not currently required by the ACA. Eleven of the 109 insurers applied exclusions to prophylactic services such as prophylactic mastectomies and removal of ovaries and fallopian tubes for women with certain genetic mutations and family history, as well as antiretroviral prophylaxis for individuals exposed to HIV or other sexually transmitted diseases—especially significant in sexual assault cases.
The report asks regulators to address these problems by prohibiting exclusions that undermine the ACA’s protections and increasing transparency in plans so women are aware of exclusions when choosing coverage. States can also prohibit substitution of benefits to ensure that states qualified health plans must offer the same benefits as the ACA’s benchmark plans.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More